HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation;HbA1c-Wert als Prädiktor für das Ergebnis der Ablation bei Diabetes mellitus Typ 2 und paroxysmalem Vorhofflimmern

Herz

Volumn 40, Issue 2, 2015, Pages 130-136

  Lu, Z H ^a   Liu, N ^a   Bai, R ^a   Yao, Y ^a   Li, S N ^a   Yu, R H ^a   Sang, C H ^a   Tang, R B ^a   Long, D Y ^a   Du, X ^a   Dong, J Z ^a   Ma, C S ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Catheter ablation; Diabetes mellitus; Glycated hemoglobin; Outcome

Indexed keywords

ANTIARRHYTHMIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABLATION CATHETER; ADULT; ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; BLOOD SAMPLING; BODY MASS; CARDIAC MAPPING SYSTEM; CATHETER ABLATION; CHADS2 SCORE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLTER MONITORING; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; REPEAT PROCEDURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VASCULAR ACCESS; ATRIAL FIBRILLATION; BLOOD; CHINA; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE FREE SURVIVAL; MIDDLE AGED; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; BIOMARKERS; CATHETER ABLATION; CHINA; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84927131101     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-014-4154-6     Document Type: Note

References (29)

1. Lip GY, Varughese GI (2005) Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 105:319–321
2. Huxley RR, Filion KB, Konety S, Alonso A (2011) Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108(1):56–62
3. Forleo GB, Mantica M, De Luca L et al (2009) Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 20(1):22–28
4. Joshi S, Choi AD, Kamath GS et al (2009) Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings. J Cardiovasc Electrophysiol 20(10):1089–1094
5. o A (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853
6. Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431
7. Iguchi Y, Kimura K, Shibazaki K et al (2012) HbA1c and atrial fibrillation: a cross-sectional study in Japan. Int J Cardiol 156(2):156–159
8. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62–S69
9. Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
10. Levy S, Maarek M, Coumel P et al (1999) Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99:3028–3035
11. Du X, Ninomiya T, Galan B de et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30:1128–1135
12. Santangeli P, Di Biase L, Al-Ahmad A et al (2012) Ablation as first-line therapy for atrial fibrillation: yes. Cardiac Electrophysiol Clin 4(3):287–297
13. Issa Z, Miller JM, Zipes DP (2012) Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease, 2nd edn. p 357
14. Hare MJL, Shaw JE, Zimmet PZ (2012) Current controversies in the use of haemoglobin A1c. J Intern Med 271:227–236
15. American Diabetes Association (2010) Standards of medical care in diabetes. Diabetes Care 33:S11–S61
16. Huxley RR, Alonso A, Lopez FL, Filion KB et al (2012) Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98(2):133–138
17. Chao TF, Suenari K, Chang SL et al (2010) Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 106:1615–1620
18. Lo LW, Tai CT, Lin YJ et al (2007) Progressive remodeling of the atrial substrate-a novel finding from consecutive voltage mapping in patients with recurrence of atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol 18:258–265
19. Vrhovac B et al (1997) Interna medicina, 2nd edn. Naprijed, Zagreb, pp 1365–1390
20. Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295(14):1681–1687
21. Liu C, Fu H, Li J et al (2012) Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg 12(7):543–550
22. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592
23. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A et al (2012) Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 157(3):397–402
24. Van Heerebeek L, Hamdani N, Handoko ML et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51
25. Kato T, Yamashita T, Sekiguchi A et al (2006) What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 17(8):890–894
26. o A (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986
27. Khaykin Y, Morillo CA, Skanes AC et al (2007) Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 18:907–913
28. Berruezo A, Tamborero D, Mont L et al (2007) Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 28:836–841
29. Shigematsu Y, Norimatsu S, Ogimoto A et al (2009) The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients. Hypertens Res 32:500–504